Journal profile · Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Molecular Oncology
ISSN 1878-0261 · John Wiley and Sons Ltd · Netherlands
Molecular Oncology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 4.43; fully open access; APC about USD 4,730; median 140 days to acceptance (85 articles, last 24 months); acceptance rate 14% (journal website); 242 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Molecular Oncology is published by John Wiley and Sons Ltd and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Genomics and Diagnostics, Cancer Cells and Metastasis and RNA modifications and cancer, together about 25.8% of its articles. Its main subfields are Cancer Research and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
For high-quality, full-length papers and expert reviews relevant to the molecular, cellular and biochemical life sciences.
From the journal's Aims & Scope
Research area (LetPub): Biochemistry, Genetics and Molecular Biology-Molecular Medicine
Editor-in-chief Kevin M. RyanPublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology11.6%
- Cancer Cells and MetastasisMedicine7.1%
- RNA modifications and cancerBiochemistry, Genetics and Molecular Biology7.1%
- Epigenetics and DNA MethylationBiochemistry, Genetics and Molecular Biology6.3%
- Cancer-related molecular mechanisms researchBiochemistry, Genetics and Molecular Biology6.1%
- Cancer-related Molecular PathwaysMedicine4.7%
- MicroRNA in disease regulationBiochemistry, Genetics and Molecular Biology4.5%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.43LetPub ·
- Impact factor (publisher) 2025
- 4.5Publisher website ·
- CiteScore 2026-06
- 9.4LetPub ·
- CiteScore (publisher) 2025
- 9.4Publisher website ·
- SJR 2026-06
- 1.74LetPub ·
- SNIP 2026-06
- 1.05LetPub ·
- h-index
- 63LetPub ·
- h-index
- 149OpenAlex ·
- i10-index
- 1,920OpenAlex ·
- 2-year mean citedness
- 3.39OpenAlex ·
- Self-citation rate
- 2.2%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 183LetPub ·
- Articles per year (publisher)
- 2Publisher website ·
- Articles per year (publisher) 2025
- 207Publisher website ·
- Downloads per year (publisher) 2025
- 1,148,459Publisher website ·
Articles by year OpenAlex count · 3,271 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 162 | 162 | 82 |
| 2025 | 242 | 242 | 542 |
| 2024 | 224 | 224 | 1,504 |
| 2023 | 227 | 227 | 2,292 |
| 2022 | 216 | 216 | 4,206 |
| 2021 | 280 | 280 | 8,151 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
140 daysMedian, submission to acceptance · P25–P75 95 days – 197 days
- Acceptance to online
- median 17 days (86 articles)
- Submission to online
- median 164 days
- Sample
- 85 articles with submission and acceptance dates (430 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 10 weeksLetPub ·
- Acceptance rate (publisher) 2025
- 14%Publisher website ·
- Submission to first decision 2025
- 1 daysPublisher website ·
- Submission to acceptance 2025
- 121 daysPublisher website ·
- Acceptance to publication 2025
- 43 daysPublisher website ·
- Submission to publication (journal-reported)
- about 10 weeksDOAJ ·
- Peer review
- Open peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 4,730 / GBP 3,170 / EUR 4,300 | Yes | CC BY | |
| OpenAlex | USD 4,300 / EUR 3,910 / GBP 2,880 | — | — | |
| LetPub | USD 3,910 / GBP 2,620 / EUR 3,550 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Article types accepted2
- research articleResearch ArticleLength not stated
- reviewReviewLength not stated
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- John Wiley and Sons Ltd
- Country or region
- Netherlands
- Language
- English
- ISSN
- 1878-0261
- Latest issue on the website
- Volume 20, Issue 9 (September 2026)
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Molecular Oncology
What CAS zone is Molecular Oncology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Molecular Oncology is in Zone 2 of Medicine, and in Zone 3 of the minor category Oncology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Molecular Oncology?
The latest impact factor listed by LetPub is 4.43; CiteScore 9.4, h-index 149.
How long does peer review take at Molecular Oncology?
Based on the dates recorded on 85 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 140 days (interquartile range 95–197 days); authors report an average review time of about 10 weeks; the journal's website gives an acceptance rate of 14% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Molecular Oncology?
According to LetPub and DOAJ records, Molecular Oncology is indexed in SCIE, Scopus and DOAJ.
Is Molecular Oncology open access, and what is the APC?
Molecular Oncology is a fully open-access journal. APC about USD 4,730.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .